Austria-based OncoOne launched with a Series A financing round worth 13 million euros ($14.26 million).

Repertoire Immune Medicines officially launched following the merger of two complementary Flagship Pioneering companies, Torque Therapeutics and Cogen Immune Medicines. The new company is focused on tapping into the powers of the immune system to address numerous diseases.

Over the next six years, 10 drugs that are in the pre-registration phase and expected to launch during 2020 are projected to reach blockbuster status.

Neurelis Inc. announced the commercial availability of Valtoco (diazepam nasal spray) for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in adult and pediatric patients 6 years of age and older.

Jeffrey Bluestone, the noted scientific researcher and pioneer in understanding T-cell activation and immune tolerance in cancer patients, stepped down from his role as chief executive of the Parker Institute for Cancer Immunotherapy to launch Sonoma Biotherapeutics.

Eli Lilly priced the company’s acute migraine treatment Reyvow at $640 for a pack of eight pills.

Leading topics of the 2020 J.P. Morgan Healthcare Conference included a general lack of big deals, defining digital health, and biopharma’s diversity problem.

EVERSANA unveiled EVERSANA ENGAGE, a full-solution healthcare marketing agency uniquely designed to help pharma and biotech companies cohesively reach patients, providers and payers to enhance patient experience and improve outcomes.

Blackstone Group Inc. is investing $400 million in a joint venture with Swiss drug company Ferring that is working on an experimental gene therapy for bladder cancer, the private equity giant’s largest-ever bet on drug development.

Moon Rabbit has launched, inspired by an ancient myth to “break boundaries for consumer and healthcare brands.”